Cautious. Seagen's 49/100 composite score reflects misaligned leadership incentives (45/100) and uncertain execution visibility. The oncology biotech faces binary clinical outcomes on key programs, yet below-median management alignment suggests potential shareholder-value leakage through dilutive equity grants or inconsistent capital allocation. Wait for clinical catalyst clarity before building conviction.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for SGEN5L.MI:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates SGEN5L.MI (SGEN5L.MI) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Seagen's 49/100 composite score reflects misaligned leadership incentives (45/100) and uncertain execution visibility. The oncology biotech faces binary clinical outcomes on key programs, yet below-median management alignment
SGEN5L.MI's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 50/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for SGEN5L.MI yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
SGEN5L.MI scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for SGEN5L.MI covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on SGEN5L.MI — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for SGEN5L.MI in the app.
